Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - thiopental sodium, quantity: 470 mg - injection, powder for - excipient ingredients: - ? as the sole anaesthetic agent for brief surgical procedures.,? induction of anaesthesia prior to the administration of other anaesthetic agents.,? short-term control of convulsive states.,? supplement to regional anaesthesia or low potency agents such as nitrous oxide.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine, quantity: 800 mg - solution - excipient ingredients: hydrochloric acid; water for injections; disodium edetate; sodium hydroxide - adjuvant therapy for patients with abnormal, viscid or inspissated mucous secretions in such conditions as: - chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung); - acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); - pulmonary complications of cystic fibrosis; - pulmonary complications associated with surgery; - post-traumatic chest conditions; - atelectasis due to mucus obstruction; - tracheostomy care; - anaesthesia. acetylcysteine may also be used as an adjunct to diagnostic bronchial studies (bronchograms, bronchospirometry and bronchial wedge catheterisation).

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine, quantity: 2000 mg - solution - excipient ingredients: disodium edetate; sodium hydroxide; water for injections; hydrochloric acid - adjuvant therapy for patients with abnormal, viscid or inspissated mucous secretions in such conditions as: - chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung); - acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); - pulmonary complications of cystic fibrosis; - pulmonary complications associated with surgery; - post-traumatic chest conditions; - atelectasis due to mucus obstruction; - tracheostomy care; - anaesthesia. acetylcysteine may also be used as an adjunct to diagnostic bronchial studies (bronchograms, bronchospirometry and bronchial wedge catheterisation).

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 20 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 2 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Israel - English - Ministry of Health

megapharm ltd - flecainide acetate - tablets - flecainide acetate 50 mg - flecainide - flecainide - serious sustained life threatening supraventricular arrhythmias that have not responded to other drugs. paroxysmal atrial fibrillation and atrial flutter